Drug Search Results
More Filters [+]

Diphencyprone

Alternative Names: diphencyprone, diphenylcyclopropenone
Latest Update: 2025-01-22
Latest Update Note: Clinical Trial Update

Product Description

Diphencyprone (DPCP) is a hapten that induces delayed-type hypersensitivity (DTH) reactions.

Mechanisms of Action: Immunomodulator

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Topical

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Nicholas Gulati
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Diphencyprone

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Vitiligo

Phase 3: Alopecia Areata

Phase 2: Melanoma|Skin Cancer

Phase 1: Hypersensitivity, Delayed|Drug Hypersensitivity|Anal Cancer|Environmental Hypersensitivity|Oncology Unspecified|Sunburn|Skin Cancer|Transplantation Unspecified|Skin Diseases, Infectious|Carcinogenesis|Stem Cell Transplant|Erythema|Melanoma|Neurofibromatoses

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

STUDY-21-01421

P1

Recruiting

Oncology Unspecified

2026-02-01

DERM-2016-25380

P3

Completed

Alopecia Areata

2024-09-01

NCT05020496

P1

Active, not recruiting

Stem Cell Transplant|Transplantation Unspecified|Anal Cancer|Environmental Hypersensitivity|Erythema|Sunburn|Carcinogenesis|Skin Cancer|Skin Diseases, Infectious

2024-06-30

STUDY-22-00650

P1

Completed

Neurofibromatoses

2023-05-17

Recent News Events